Abstract
Purpose
Few data on the efficacy and safety of drugs in children are available as in the past, these children were not included in randomized controlled trials (RCTs). Data on the efficacy and safety of drugs in children are extrapolated from adults. The EMA recognizes the need for long-term safety studies on various drugs, a need that can best be answered by pharmacoepidemiological studies. In this article, we provide currently available information on study designs within the field of paediatric drug research.
Methods
A PubMed search was conducted on all pharmacoepidemiological studies in children. In addition, data from handbooks on pharmacoepidemiology were consulted. Data were reviewed and the relevant literature on study designs in paediatric pharmacoepidemiology is described.
Results
The various study designs in pharmacoepidemiology have their specific indications, all with their specific limitations. Case reports and case series are mainly used for signal detection of safety issues whereas case control and cohort studies are used for safety hypothesis testing. Observational studies can be conducted using data from automated databases that guarantee large sample size and long-term follow-up, which is ideal for safety studies, especially in case of rare events.
Conclusion
Pharmacoepidemiological studies are crucial in research on the safety of drugs in children. Knowledge of the different pharmacoepidemiological methods is important to guarantee optimal use and correct interpretation of the data.
Similar content being viewed by others
References
World Health Organization (2007) Promoting safety of medicines in children. WHO Press, Geneva
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167
EMEA www.emea.europe.eu
FDA. Paediatric drug development. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm
EMEA. Medicines for children—EU paediatric network. www.emea.europa.eu/htms/human/paediatrics.network.htm
EMEA. Inventory of paediatric needs. http://www.ema.europa.eu/ema/index
Hartzema AG, Tilson HH, Chan KA (2008) Pharmaco-epidemiology and therapeutic risk management. Whitney, Cincinnati, OH
Strom BL, Kimmel SE (2006) Textbook of pharmacoepidemiology. Wiley, New York
TEDDY, www.teddynoe.org
Taussig HB (1962) A study of the German outbreak of phocomelia. The thalidomide syndrome. JAMA 180:1106–1114
Herbst AL, Ulfelder H, Poskanzer DC (1971) Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284(15):878–881
Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365(9458):475–481
Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330(7504):1366
Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165(9):978–984
Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142(7):481–489
Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360(9339):1071–1073
Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109(17):2068–2073
Torrence ME (1997) Understanding epidemiology. Mosby, St. Louis, MI
Caine ED, Margolin DI, Brown GL, Ebert MH (1978) Gilles de la Tourette's syndrome, tardive dyskinesia, and psychosis in an adolescent. Am J Psychiatry 135(2):241–243
Mizrahi EM, Holtzman D, Tharp B (1980) Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. Arch Neurol 37(12):780
Petty LK, Spar CJ (1980) Haloperidol-induced tardive dyskinesia in a 10-year-old girl. Am J Psychiatry 137(6):745–746
Likasitwattanakul S (2005) Serotonin syndrome: a case report. J Med Assoc Thai 88(7):993–996
Phan H, Casavant MJ, Crockett S, Lee A, Hall MW, Nahata MC (2008) Serotonin syndrome following a single 50 mg dose of sertraline in a child. Clin Toxicol (Phila) 46(9):845–849
Ziaee V, Akbari Hamed E, Hoshmand A, Amini H, Kebriaeizadeh A, Saman K (2005) Side effects of dextromethorphan abuse, a case series. Addict Behav 30(8):1607–1613
Lin S, Gomez MI, Hwang SA, Munsie JP, Fitzgerald EF (2008) Self-reported home environmental risk factors for childhood asthma: a cross-sectional study of children in Buffalo, New York. J Asthma 45(4):325–332
Liberman JN, Berger JE, Lewis M (2009) Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents. Arch Pediatr Adolesc Med 163(4):357–364
Ashby D (2008) Establishing causality in the assessment of safety of medicines for children. Acta Paediatr 97(12):1611–1616
Luo X, Doherty J, Cappelleri JC, Frush K (2007) Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics. Curr Med Res Opin 23(11):2607–2615
van Staa TP, Bishop N, Leufkens HG, Cooper C (2004) Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 15(10):785–791
Sturkenboom M, Nicolosi A, Cantarutti L, Mannino S, Picelli G, Scamarcia A, Giaquinto C; NSAIDs Paediatric Research Group (2005) Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics 116(1):e26–e33
Furu K, Skurtveit S, Langhammer A, Nafstad P (2007) Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol 63(7):693–698
Fox MH, Foster CH, Zito JM (2000) Building pharmacoepidemiological capacity to monitor psychotropic drug use among children enrolled in Medicaid. Am J Med Qual 15(4):126–136
Hugtenburg JG, Heerdink ER, Egberts AC (2004) Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol 60(5):377–379
Thrane N, Sorensen HT (1999) A one-year population-based study of drug prescriptions for Danish children. Acta Paediatr 88(10):1131–1136
Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, Picelli G, Sen EF, Giaquinto C, Cantarutti L, Baiardi P, Felisi MG, Ceci A, Wong IC; TEDDY European Network of Excellence (2008) Drug use in children: cohort study in three European countries. BMJ 337:a2245
Mikaeloff Y, Kezouh A, Suissa S (2008) Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol 65(2):203–209
Lindquist M, Edwards IR (2001) The WHO programme for International drug monitoring, its database, and the technical support of the Uppsala monitoring center. J Rheumatol 28(5):1180–1187
Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Nicolosi A, Giaquinto C, Ceci A, Wong IC; TEDDY Network of Excellence (2008) Databases for pediatric medicine research in Europe–assessment and critical appraisal. Pharmacoepidemiol Drug Saf 17(12):1155–1167
Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, Giaquinto C, Knibbe CA, Sturkenboom MC, Ghaleb MA, Ceci A (2008) Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res 58(5–6):316–322
Chalumeau M, Gendrel D, Bréart G, Pons G (2004) An example of hospital-based pharmacoepidemiology in paediatrics: tolerance to fluoroquinolones. Arch Pediatr 11(6):500–502
'T Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Stricker BH (2002) Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ 324(7349):1313–1314
McIntyre J, Conroy S, Avery A, Corns H, Choonara I (2000) Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 83(6):498–501
Evidence of harm from off label or unlicensed medicines in children. www.emea.europe.eu/pdfs/human/phvwp/23591005en.pdf
EMEA. ICH Topic E 11: Clinical Investigation of Medicinal Products in the Paediatric Population. www.emea.europa.eu/pdfs/human/ich/271199en.pdf
Almqvist C, Worm M, Leynaert B (2008) Impact of gender on asthma in childhood and adolescence: a GA2LEN review. Allergy 63(1):47–57
Colvin L, Slack-Smith L, Stanley FJ, Bower C (2009) Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 18(3):211–225
Conflict of interest
As employees of Erasmus MC, MCJMS and KMCV have been involved as project leader and in analyses contracted by various pharmaceutical companies, and received unconditional research grants from Pfizer, Merck, Johnson&Johnson, Amgen, Roche, GSK, Boehringer, Yamanouchi and Altana, none of which are related to the subject of this paper.
Author information
Authors and Affiliations
Corresponding author
Additional information
On behalf of the TEDDY European Network of Excellence
Rights and permissions
About this article
Cite this article
Verhamme, K., Sturkenboom, M. Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol 67 (Suppl 1), 67–74 (2011). https://doi.org/10.1007/s00228-010-0930-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0930-2